Bangalore, India; April 19, 2023: Glenmark Pharmaceuticals Ltd. (Glenmark), an innovation-driven, global pharmaceuticals company, has further strengthened its position in the respiratory segment and is ranked #2 in the Indian pharma market*. Glenmark is a trusted brand for its respiratory medicines with brands like Ascoril, Ascoril LS, Ascoril D and Alex. The company's modern and innovative solutions, Bilazap M and Ryaltris AZ/Mono are also popular among patients and healthcare professionals. Over the past one year, its respiratory medicines have been prescribed by more than 1 lakh medical professionals and has helped over 4 crore patients from all age groups across the country.

Glenmark has been a pioneer in modern OAD (Obstructive Airway Disease) management in India, and is one of the first companies to address unmet patient needs in asthma and COPD - Chronic Obstructive Pulmonary Disease in the country. Glenmark has been the first to introduce innovative products in the chronic respiratory space with the launch of Digital Dose Inhalers, Ultra LABA + ICS, Single Inhaler Triple Therapy, and Nebulised LAMA. These solutions have helped patients with chronic respiratory conditions breathe better and manage their symptoms more effectively.

Mr. Alok Malik, Executive Vice President and India Business Head at Glenmark Pharmaceuticals Ltd, said, “Our innovative products and patient-centric approach have been instrumental in strengthening our position as one of the leaders in the respiratory segment, in the Indian Pharmaceutical Industry. We are driven by our goal of providing first-in-market medicines for our patients and will continue to bring new medicines that are safe and effective.”

Over the years, the company’s Ascoril brand has grown multifold, having won numerous Guinness World Records for its awareness campaigns. Glenmark's position as one of the leaders in the respiratory segment reflects the Company's commitment to providing innovative and effective solutions for respiratory ailments.

As per an analysis of the Global Burden of Disease data1, India has 32% of the global burden of respiratory diseases and pollution has been the biggest contributor to this burden.

About Glenmark Pharmaceuticals Ltd.

Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is an innovation‐driven, global pharmaceutical company with a presence across Branded, Generics, and OTC segments; with a focus on therapeutic areas of respiratory, dermatology and oncology. The company has 10 world‐class manufacturing facilities spread across 4 continents, and operations in over 80 countries. In Vivo/Scrip 100 positions Glenmark amongst the Top 100 Companies Ranked by R&D and Pharmaceutical Sales, 2021; while Generics Bulletin/In Vivo places it in the Top 50 Generics and Biosimilars Companies Ranked by Sales, 2021. The company has been Great Place To Work® Certified™ in India, in 2023. Glenmark has impacted over 2.6 million lives over the last decade through its CSR interventions.

*Disclamier: "The pages slugged ‘Press Release’ are equivalent to advertisements and are not written and produced by Success Insights India Media journalists/Editorial." We do not hold any copyrights towards the content or image. Image source: Newswire